Block Listing Review & Total Voting Rights

ReNeuron Group plc

01 March 2024

 

01 March 2024

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 September 2023 to 29 February 2024
Balance of unallotted securities under scheme(s) from previous return:	8,600,000 Ordinary Shares (of 1p each)
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	-
Less: Number of securities issued/allotted under scheme(s) during period	-
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	8,600,000 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Total Voting Rights

At 29 February 2024, the Company had 57,173,760 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,173,760 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

ReNeuron		www.reneuron.com/investors
Iain Ross, Executive Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser and Broker)		[phone]
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.  

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

 

END